Home > Healthcare & Medical Devices > Liver Cancer Diagnostics Market

Liver Cancer Diagnostics Market - By Test Type (Laboratory Test, Imaging Test, Biopsy, Endoscopy, Genomic Test), By End-use (Hospitals, Diagnostic Laboratories, Academic and Research Institutes), & Forecast, 2023 – 2032

  • Report ID: GMI6100
  • Published Date: Jun 2023
  • Report Format: PDF

Liver Cancer Diagnostics Industry Analysis

Liver Cancer Diagnostics Market size recorded USD 10.5 billion in 2022 and is likely to witness 7% CAGR from 2023 to 2032. This incremental growth rate is owing to increasing prevalence of liver cancer and other chronic conditions in line with rising awareness and screening programs targeting high-risk populations.

Liver Cancer Diagnostics Market

To get more details on this report: Request Free Sample PDF

Technological advancements pertaining to liver cancer diagnostics and screening procedures has influence the product adoption rate in several healthcare facilities. Increasing awareness and initiatives to cater to appropriate diagnostic treatments and clinical benefits offered by liver cancer diagnostics will propel the market growth.

Manufacturers are focusing on providing a wide range of diagnostic products, including imaging technologies, biomarker tests, genetic profiling, and liquid biopsy solutions for liver cancer detection and monitoring. Screening programs targeting high-risk populations help in early detection, leading to improved patient outcomes. Thus, increasing investments aim to develop novel biomarkers, improve imaging techniques, and government initiatives enhance the overall diagnostic accuracy thereby fueling the liver cancer diagnostics market growth.

High-cost diagnostic tests may pose financial challenges for patients, especially those without adequate insurance coverage or in regions with limited healthcare resources. The affordability barrier may prevent some individuals from accessing timely liver cancer diagnostics, leading to delayed or missed diagnoses. High-cost diagnostic tests can strain healthcare systems and budgets, particularly in countries with limited healthcare resources. Reimbursement policies and coverage limitations by healthcare payers can also contribute to the cost constraint.

COVID-19 Impact

The recent outbreak of COVID-19 had negatively influenced the liver cancer diagnostics market revenue, specifically during the initial phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during the pandemic phase. These conditions severely impacted the market revenue share. Several hospitals and healthcare facilities globally experienced a significant decline in patient visits for diagnosis and treatment of liver cancer, other chronic conditions. Non-urgent medical procedures and screenings, including liver cancer diagnostics, were postponed or canceled to prioritize resources for COVID-19 patients. This disruption in screening and diagnosis may have led to delayed detection of liver cancer and missed opportunities for early intervention.

The outbreak of COVID-19 pandemic disrupted the spectrum of cancer care, as screening program and services were suspended or decreased in many countries. The liver cancer diagnostics industry relies on the availability of diagnostic tests, reagents, and equipment. The global supply chain disruptions caused by COVID-19, including manufacturing delays, transportation restrictions, and increased demand for certain medical supplies, negatively affected the availability and timely delivery of liver cancer diagnostic products. Reducing COVID-19 infection rates and patients, as well as increased procedural volume, are predicted to aid market growth.

Liver Cancer Diagnostics Market Trends

Increasing prevalence of liver cancer is accelerate the demand for liver cancer diagnostics across the globe. Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are major risk factors for liver cancer. The global burden of these infections is significant, and individuals with chronic hepatitis B or C are at a higher risk of developing liver cancer. For instance, according to the CDC data, in 2021, around 296 million people were suffering from hepatitis B and is projected to increase in the near future. Additionally, 25% of chronic hepatitis B infections progress to liver cancer thereby augmenting the product demand. The increasing prevalence of these infections contributes to the growing pool of individuals who require liver cancer diagnostics.

Growing adoption of unhealthy diet including excessive fat and sugar content coupled with lack of physical exercise and consumption of excessive alcohol has escalated the number of people suffering from chronic conditions such as diabetes and cancer. The growing prevalence of obesity and metabolic syndrome worldwide contributes to the rising incidence of liver cancer and drives the need for liver cancer diagnostics. Early detection and diagnosis of liver cancer play a crucial role in improving patient outcomes by enabling timely treatment interventions. The growing demand for liver cancer diagnostics is propelled by the need to detect liver cancer at an early stage, assess its severity, and guide appropriate treatment strategies.

Liver Cancer Diagnostics Test Type Segmentation

Liver Cancer Diagnostics Market Size, By Test Type,

To get more details on this report: Request Free Sample PDF

Based on test type, the market is segmented as laboratory test, imaging test, biopsy, endoscopy, genomic test and others. The laboratory test segment dominated the liver cancer diagnostics market accounting over 32% revenue share in 2022. Laboratory tests for liver cancer diagnostics provide several benefits in the detection, diagnosis, and monitoring of hepatocellular carcinoma. Laboratory tests, such as blood tests and biomarker assays, can aid in the early detection of liver cancer. These tests can identify specific markers or molecules that are associated with liver cancer, even before symptoms manifest.

Early detection allows for timely intervention and treatment, which can improve patient outcomes and increase the chances of successful treatment. Laboratory tests play a crucial role in screening high-risk individuals for liver cancer and in surveillance for individuals with chronic liver diseases. For instance, individuals with chronic hepatitis B or C infections, alcoholic liver disease, or non-alcoholic fatty liver disease (NAFLD) may undergo regular liver function tests and biomarker tests to monitor liver health and detect any signs of liver cancer development.

Laboratory tests aid in staging liver cancer and determining the extent of disease spread. Biomarker tests, such as alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), can provide information about tumor markers and help assess the prognosis of liver cancer patients. These tests assist healthcare providers in making informed decisions regarding treatment options and disease management. Laboratory tests in liver cancer diagnostics provide valuable information for early detection, screening, differential diagnosis, disease staging, treatment monitoring, and personalized medicine thereby augmenting the market growth.

Liver Cancer Diagnostics End-use Segmentation

Liver Cancer Diagnostics Market Share, By End-use,

To get more details on this report: Request Free Sample PDF

Based on end-use, the liver cancer diagnostics market is segmented as hospitals, diagnostic laboratories, academic and research institutes and others. The hospitals segment captured a majority market share and is poised to grow at 7% CAGR through 2032. High adoption rates for technologically advanced biopsy, mammography, and other devices utilized in treatment of liver cancer will increase the number of diagnosis carried out in hospital settings. Availability of skilled professionals to operate advanced cancer diagnosis equipment as well as favorable reimbursement policies for liver cancer diagnosis procedures performed in hospital settings will surge the segment revenue.

Hospitals are adopting advanced diagnostic technologies such as biomarker assays, genetic profiling, and liquid biopsy techniques to improve the quality of patient care and outcomes. The management of liver cancer often requires a multidisciplinary approach involving various medical specialties, including hepatology, radiology, pathology, and oncology.

Hospitals are adopting liver cancer diagnostics to support collaboration and coordination among different departments, enabling accurate diagnosis, staging, and treatment planning. Furthermore, factors such as increase in the number of liver cancer diagnostic procedures and the availability of highly skilled healthcare professionals together with robust healthcare infrastructure and appropriate patient assistance that are complementing the growth of the hospitals segment positively. Thus, access to better treatment and diagnosis, combined with the increased prevalence of liver cancer, is expected to increase patient visits to hospitals, propelling segment revenue.

Liver Cancer Diagnostics Regional Analysis

North America Liver Cancer Diagnostics Market Size,

North America region held a dominant share in the global liver cancer diagnostics market and was valued at USD 4.4 billion in 2022. North America has a significant prevalence of risk factors associated with liver cancer, such as chronic hepatitis B and C infections, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). These risk factors contribute to the increasing incidence of liver cancer in the region, necessitating the demand for effective liver cancer diagnostics for early detection and intervention. Technological advancement in cancer diagnostic techniques, favorable R&D initiatives by industry players and government’s support towards development of advanced diagnostic platforms will favor industry growth.

Growing awareness among people regarding early disease diagnosis, availability of advanced healthcare infrastructure along with high healthcare expenditure will stimulate North America liver cancer diagnostics market growth. Aging population, increased awareness of preventive healthcare, and advancements in liver cancer diagnostics techniques is anticipated to boost the market growth. Thus, supporting initiatives aimed at improving healthcare outcomes, rising healthcare expenditure, and increasing disease prone population would drive the regional market revenue share positively.

Liver Cancer Diagnostics Industry Leaders

Some of the major players operating in the liver cancer diagnostics market are AB SCIEX, Agilent Technologies Inc., Becton, Dickinson & Company, Biocare Medical, LLC, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Epigenomics Ag, F. Hoffmann-La Roche Ltd., General Electric Company, Hoffmann La-Roche Ltd., Hologic, Inc., Johnson & Johnson, Koninklijke Philips N.V., Qiagen N.V., Seimens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Inc. among others. These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion.

Liver Cancer Diagnostics Industry News:

  • In January 2023, Fujifilm Corporation announced the acquisition of Inspirata, Inc., a company engaged in digital pathology business. This acquisition helped the company to streamline care delivery for oncology patients and provider teams. This strategic move helped the company to enhance their R&D capabilities and increase their business revenue.
  • In February 2019, Abbott Laboratories announced that they had received the CE Mark approval for their Determine HBsAg 2, a rapid diagnostic test for the detection of hepatitis B surface antigen. This test highly sensitive, easy-to-use, rapid lateral flow test enables identification of hepatitis B virus (HBV) thereby enabling the detection and pre diagnosis of liver cancer among high-risk patients. This approval helped the company to enhance their customer base and increase their geographic presence.

This Liver cancer diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Test Type

  • Laboratory Test
    • Biomarkers
    • Blood Tests
  • Imaging Test
  • Biopsy
  • Endoscopy
  • Genomic Test
  • Others

By End-use

  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Poland
    • Sweden
    • The Netherlands
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
    • Peru
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Egypt
    • Turkey


Authors: Rupali Swain, Shishanka Wangnoo

Frequently Asked Questions (FAQ) :

The market size of liver cancer diagnostics was worth more than USD 10.5 billion in 2022 and is estimated to reach USD 20.7 billion by 2032 driven by the high prevalence of liver cancer coupled with the rising awareness and screening programs.

The laboratory test segment accounted for more than 32% of the liver cancer diagnostics market share in 2022 and is set to record substantial growth through 2032 owing to the benefits of early detection of liver cancer through lab tests to enable timely intervention and treatment.

North America market for liver cancer diagnostics generated USD 4.4 billion in 2022 and is poised to grow at a notable CAGR from 2023 to 2032 owing to the increasing technological advancement in cancer diagnostic techniques and favorable R&D initiatives.

Some of the major liver cancer diagnostics business players include AB SCIEX, Agilent Technologies Inc., Becton, Dickinson & Company, Biocare Medical, LLC, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Epigenomics Ag, F. Hoffmann-La Roche Ltd., and General Electric Company.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 18
  • Tables & Figures: 275
  • Countries covered: 30
  • Pages: 160
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount